Prashant Reddy

Prashant Reddy

T. Prashant Reddy graduated from the National Law School of India University, Bangalore, with a B.A.LLB (Hons.) degree in 2008. He later graduated with a LLM degree (Law, Science & Technology) from the Stanford Law School in 2013. Prashant has worked with law firms in Delhi and in academia in India and Singapore. He is also co-author of the book Create, Copy, Disrupt: India's Intellectual Property Dilemmas (OUP).

Drug Regulation

The DCGI is preparing a document to implement the patent-registration linkage system


Readers may remember that SpicyIP had recently carried an extensive post in regards the ‘Patent-Registration’ linkage system that was proposed by the DGCI. Pharmabiz.com reported a couple of days ago that the DCGI is preparing a document outlining a system to implement the linkage system. Once the document is ready the DCGI has promised to make it available to the industry for debate and discussion to ensure that everybody’s interests are protected. The pharmabiz.com report also informs us that the…


Read More »
Drug Regulation Patent

Why is the DCGI trying to implement a ‘patent-registeration’ linkage system in India?


The Drug Controller General of India – Dr. Surinder Singh – has made a public statement that he intends to link up regulatory approval for drugs to the patenting system i.e. he has gone on to record to state that the DCGI will not grant regulatory approval for generic drugs if in case the innovator drug still has a valid patent covering it. Such a move would severely delay the entry of generics into the market. (The Mint, the Business…


Read More »

SpicyIP Tidbit: The ‘Public Interest’ factor in Brazil’s patenting system


IMAK’s Tahir Amin has written an incisive piece on the hurdles being faced by Gilead in its quest to patent Tenofovir in Brazil and the possible spin-offs for Indian companies in the process. What caught our eye however was the ‘public interest’ factor which Mr. Amin mentioned in his post. According to Mr. Amin when a patent is being granted in Brazil, apart from the conventional patent office approval, the invention if it is a pharmaceutical product will also be…


Read More »

SpicyIP Tidbit: Minister to ensure that reduced excise duty to reflect in drug prices


The Minister of Chemicals and Fertilisers Ram Vilas Paswan, who heads the pharmaceutical advisory forum has instructed drug companies that they will have to reduce their prices by atleast 4.58% since the excise duty on drugs has been scaled back from 16% to 8%. He also promised to strengthen the infrastructure of the pricing watch-dog – the National Pharmaceutical Pricing Authority (NPPA) – by introducing a 24 hour helpline for customers who want to complain about drug companies over-charging on…


Read More »

SpicyIP Tidbit: Appeals Court rules on two issues in the Roche-Cipla litigation


The Mint and the ET report that a division bench of the Delhi High Court, hearing Roche’s appeal against the judgment of the single judge, have restained Cipla from exporting Erlocip to any country where Roche already has a patent for the drug. This is a mere restatement of the obvious and more over its a moot point as to whether the issue of export is even within the jurisdiction of the Delhi High Court. If Cipla does export to…


Read More »

Roche v. Cipla: The ‘Mint’ interviews Roche India’s MD on the recently concluded Tarceva litigation


The Mint recently carried an interview of Mr. Girish Telang, managing director of Roche Scientific India Pvt Ltd, the Indian unit of Switzerland-based F Hoffmann-La Roche Ltd. Incidentally this interview seems to be one of the few public statements by Roche, in regards, its high profile litigation against Cipla over Tarceva. (We’ve blogged about the Roche v. Cipla litigation here.) SpicyIP however was rather surprised by the re-statement of some facts by Mr. Telang, since all these facts were very…


Read More »

India-USPTO conference on TK & patenting kicks off in New Delhi


The Financial Express reports that India, the United States Patents & Trademark Office (USPTO) along with representatives of Saarc countries and WIPO are having a three day conference in New Delhi to deal with developing countries concerns in regards the protection of traditional knowledge (TK), genetic resources & folklore – all of them being subjects not adequately covered by TRIPS. Readers may remember that Sumati had, way back in Novemebr 2007, pointed out to an ET article on the efforts…


Read More »

SpicyIP Events: NLSIU Symposium on ‘Challenges to India’s Patent Regime’ being held on April 12th-13th


A couple of months ago, SpicyIP Events had brought to your attention that the National Law School of India University was organizing a Symposium on ‘Challenges to India’s Patent Regime’ on the 12th-13th of April. Billed as one of the ‘spiciest’ IP events of the year this NLSIU Symposium boasts an excellent line-up of speakers, most of them being the authorities in their respective fields. Keeping in line with the highest traditions of legal debate at the NLSIU this Symposium…


Read More »

Natco & Compulsory Licenses: Round 3


Unnikrishnan of the Mint reports that we may see a third compulsory licensing case in the coming days. No prizes for guessing the identity of the applicant. Yes, its Natco once again! Our readers may remember that the two previous applications by Natco were for two anti-cancer drugs being manufactured by Roche and Pfizer. In those two cases Natco had filed for a CL to export to Nepal. This time round however Natco is applying for a CL to manufacture…


Read More »

Govt. in favour of compulsory licensing only in cases of emergencies


The ET reports that the Government is in favour of using compulsory licensing only in emergencies. The report quotes a senior official of the DIPP (which controls the patent office) as saying “We are not in favour of CL unless there is an extraordinary problem. There is no point in going in for CL unless there is an epidemic which impacts a large chunk of the population, and needs immediate solution “. When asked whether a disease like cancer qualifies…


Read More »